Rilonacept (IL-1R1 Fc protein), anakinra (recombinant IL-1 RA), and canakinumab (anti-IL-1 mAb) are protein-based therapeutics that are currently accepted as anti-IL-1 therapies [189]. Here, IL1A is linked to rheumatoid arthritis.